T. Rowe Price Associates’s Cullinan Oncology CGEM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $275K | Buy |
36,417
+4,696
| +15% | +$35.5K | ﹤0.01% | 2566 |
|
|
2025
Q1 | $241K | Buy |
31,721
+2,228
| +8% | +$16.9K | ﹤0.01% | 2555 |
|
|
2024
Q4 | $360K | Buy |
29,493
+3,924
| +15% | +$47.9K | ﹤0.01% | 2419 |
|
|
2024
Q3 | $429K | Buy |
25,569
+4,770
| +23% | +$80K | ﹤0.01% | 2321 |
|
|
2024
Q2 | $363K | Sell |
20,799
-2,043
| -9% | -$35.7K | ﹤0.01% | 2325 |
|
|
2024
Q1 | $390K | Buy |
22,842
+820
| +4% | +$14K | ﹤0.01% | 2308 |
|
|
2023
Q4 | $225K | Buy |
22,022
+7,620
| +53% | +$77.9K | ﹤0.01% | 2490 |
|
|
2023
Q3 | $131K | Hold |
14,402
| – | – | ﹤0.01% | 2603 |
|
|
2023
Q2 | $155K | Buy |
14,402
+365
| +3% | +$3.93K | ﹤0.01% | 2592 |
|
|
2023
Q1 | $144K | Sell |
14,037
-15
| -0.1% | -$154 | ﹤0.01% | 2607 |
|
|
2022
Q4 | $148K | Buy |
14,052
+435
| +3% | +$4.58K | ﹤0.01% | 2621 |
|
|
2022
Q3 | $175K | Buy |
13,617
+1,871
| +16% | +$24K | ﹤0.01% | 2586 |
|
|
2022
Q2 | $151K | Buy |
11,746
+619
| +6% | +$7.96K | ﹤0.01% | 2655 |
|
|
2022
Q1 | $116K | Buy |
11,127
+500
| +5% | +$5.21K | ﹤0.01% | 2816 |
|
|
2021
Q4 | $164K | Buy |
+10,627
| New | +$164K | ﹤0.01% | 2798 |
|
|
2021
Q2 | – | Sell |
-723,584
| Closed | -$30.2M | – | 2918 |
|
|
2021
Q1 | $30.2M | Buy |
+723,584
| New | +$30.2M | ﹤0.01% | 1168 |
|